Alzheimer's drug rejected by EMA

The Alzheimer's drug lecanemab has not been approved by the European Medicines Agency EMA. The benefits are not considered to outweigh the potential drawbacks. A review of the decision will be requested, announces Swedish Bioarctic – whose share plummeted on the news.

» Updated:

» Published:

Alzheimer's drug rejected by EMA
Photo: Martina Holmberg/TT

Share this article

The Alzheimer's drug lecanemab has not been approved by the European Medicines Agency (EMA). The benefits are not considered to outweigh the potential drawbacks.

A review of the decision will be requested, announces Swedish Bioarctic – whose stock plummeted on the news.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) believes that the observed effect of slowing down cognitive decline does not outweigh the risk of serious side effects associated with the medicine.

"This particularly concerns the frequent occurrence of amyloid-related imaging abnormalities, which include swelling and potential bleeding in the brain of patients who received the drug," the decision states.

Lecanemab, marketed under the brand name Leqembi, has been developed by the American pharmaceutical company Biogen and Japanese Eisai. The drug is based on a discovery by the Swedish pharmaceutical company Bioarctic, which holds a royalty on the global sales of lecanemab.

"We are surprised and very disappointed over CHMP's statement today," says Bioarctic's CEO Gunilla Osswald in a press release, and continues:

"However, this is not the final verdict, and our partner Eisai will request a review of CHMP's statement and continue working with authorities to ensure that the treatment becomes available to eligible individuals living with early Alzheimer's disease in the EU as soon as possible."

The drug has previously been approved in the USA, Japan, China, South Korea, Hong Kong, and Israel.

It is the EU Commission that ultimately makes the legally binding decision on marketing authorization for drugs. The decision is based on the European Medicines Agency's recommendation.

Alzheimer's is an incurable dementia disease. Approximately 100,000 Swedes, almost all over 65 years old, live with the disease, according to the Brain Foundation.

After the news, Bioarctic's stock plummeted, falling 34.3 percent on Friday.

Lecanemab is an antibody targeting a variant of a protein called beta-amyloid. Accumulations of beta-amyloid in the brain are believed by many researchers to cause Alzheimer's disease.

Earlier, several other antibodies targeting beta-amyloid have failed to slow down the disease progression. Lecanemab works by targeting a specific variant of the protein, so-called protofibrils, which researchers behind the drug believe are particularly harmful.

The drug is based on a discovery by Swedish researcher Lars Lannfeldt, professor at Uppsala University. His research group identified a change in the genetic material of a northern Swedish family severely affected by Alzheimer's disease.

The drug has been developed, among others, by the Swedish company Bioarctic, which Lars Lannfeldt co-founded.

Source: Uppsala University, Bioarctic

Tags

Author

TTT
By TTEnglish edition by Sweden Herald, adapted for local and international readers

More news

Two Men Who Escaped Borås Detention Still at Large

Two Men Who Escaped Borås Detention Still at Large

Västernorrland Uses Satellite Support to Assess Flood Impact

Västernorrland Uses Satellite Support to Assess Flood Impact

Mother of Six Finds Solace in City Mission's Support

Mother of Six Finds Solace in City Mission's Support

Police Launch National Security Measures for 2026 Election

Police Launch National Security Measures for 2026 Election

Suspected Hazardous Object Secured in Malmö's Hyllie District

Suspected Hazardous Object Secured in Malmö's Hyllie District

Kristersson Responds to Orbán's Claims: "Horrifying Lies"

Kristersson Responds to Orbán's Claims: "Horrifying Lies"

Government Boosts Environmental Compensation for Freight Trains

Government Boosts Environmental Compensation for Freight Trains

More Voters Expected in Next Year's Swedish Election

More Voters Expected in Next Year's Swedish Election

Pandemic Face Masks Pose Environmental Risk with Microplastics and Chemicals

Pandemic Face Masks Pose Environmental Risk with Microplastics and Chemicals

Teen Girl Stabbed in Borås; Suspect of Same Age Arrested

Teen Girl Stabbed in Borås; Suspect of Same Age Arrested

Algal Bloom Crisis Worsens at British Isles' Largest Lake Lough Neagh

Algal Bloom Crisis Worsens at British Isles' Largest Lake Lough Neagh

Man in His 70s Dies in Drowning Accident at Motala Beach

Man in His 70s Dies in Drowning Accident at Motala Beach

Government Plans to Add Chickenpox Vaccine to Child Vaccination Program

Government Plans to Add Chickenpox Vaccine to Child Vaccination Program

Gang Leader Among Two Escapees from Borås Detention Center

Gang Leader Among Two Escapees from Borås Detention Center

Stolen Swedish Data from Miljödata Leaked on Darknet, Expert Warns

Stolen Swedish Data from Miljödata Leaked on Darknet, Expert Warns

How to Avoid Salmonella: Tips for Safe Egg and Food Handling

How to Avoid Salmonella: Tips for Safe Egg and Food Handling

Södermalm Explosion Deemed a Misfire by Police

Södermalm Explosion Deemed a Misfire by Police

Hackers Threaten to Release Personal Data After Miljödata Breach

Hackers Threaten to Release Personal Data After Miljödata Breach

Gotland Braces for Heavy Rain as SMHI Issues Yellow Warning

Gotland Braces for Heavy Rain as SMHI Issues Yellow Warning

Swedish Potato Farmers Face PFAS Dilemma Amid Consumer Demands

Swedish Potato Farmers Face PFAS Dilemma Amid Consumer Demands